Stifel reiterates Buy on Sportradar stock after divestiture
Stifel maintained its Buy rating and $18.00 price target on Sportradar (SRAD) after its divestiture announcement, citing portfolio optimization. The stock is near its 52-week low at $11.79, with a potential 53% upside. The divested business is valued at 11x 2026 adjusted EBITDA, higher than Sportradar's current 8.5x multiple. Analysts highlight the company's strategic moves and partnerships, including an expanded deal with Polymarket.
How this was made
The 30-second read
Why it matters
Analyst upgrade and higher price target suggest fresh upside potential; the divestiture is framed as portfolio optimization.
Market read
The announcement provides a new catalyst for SRAD, potentially driving short‑term price appreciation.
What to watch
Execution risk of the sale and potential loss of cross‑selling opportunities with existing betting products.
Background
Stifel maintains its Buy rating on Sportradar (SRAD) after the company announced the sale of its low‑growth coaching analytics unit, retaining core camera technology.
Ticker impact
Stifel reiterated a Buy rating and $18 price target after Sportradar announced the divestiture of its coaching and scouting analytics business.
likely upward pressure as the market prices in the accretive valuation of the divestiture.
Analyst upgrade with a sizable price target increase (53% upside) signals fresh buying interest.
Market effects
Highlights a trend of sports‑data firms pruning non‑core assets to improve margins, potentially prompting peers to consider similar moves.
May boost sentiment for US‑listed tech and data‑service stocks, especially those with exposure to Latin America.
Limited to the niche sports‑analytics sector; broader market impact is modest.
Counterpoint
The divestiture could signal underlying weakness in the coaching analytics segment, and the market may already price in the benefit.
Key entities
- companySportradar Group AG
Provider of sports data and betting technology, ticker SRAD.
- analystStifel
Equity research firm reiterating a Buy rating with a $18 target.
